Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 467

1.

Evaluating non-invasive markers to identify advanced fibrosis by liver biopsy in HBV/HIV coinfected adults.

Sterling RK, King WC, Wahed AS, Kleiner DE, Khalili M, Sulkowski M, Chung RT, Jain MK, Lisker-Melman M, Wong DK, Ghany MG; HIV-HBV Cohort Study of the Hepatitis B Research Network.

Hepatology. 2019 Jun 20. doi: 10.1002/hep.30825. [Epub ahead of print]

PMID:
31220357
2.

Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals.

Naggie S, Fierer DS, Hughes MD, Kim AY, Luetkemeyer A, Vu V, Roa J, Rwema S, Brainard DM, McHutchison JG, Peters MG, Kiser JJ, Marks KM, Chung RT; Acquired Immunodeficiency Syndrome Clinical Trials Group (ACTG) A5327 Study Team .

Clin Infect Dis. 2019 Mar 28. pii: ciy913. doi: 10.1093/cid/ciy913. [Epub ahead of print]

PMID:
31220220
3.

Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals.

Perez S, Kaspi A, Domovitz T, Davidovich A, Lavi-Itzkovitz A, Meirson T, Alison Holmes J, Dai CY, Huang CF, Chung RT, Nimer A, El-Osta A, Yaari G, Stemmer SM, Yu ML, Haviv I, Gal-Tanamy M.

PLoS Genet. 2019 Jun 19;15(6):e1008181. doi: 10.1371/journal.pgen.1008181. [Epub ahead of print]

4.

Editorial: mind the gaps - an important first step towards improving hepatic encephalopathy care.

Bloom PP, Chung RT.

Aliment Pharmacol Ther. 2019 Jun;49(12):1534-1535. doi: 10.1111/apt.15290. No abstract available.

PMID:
31134647
5.

Evaluation of model performance to predict survival after transjugular intrahepatic portosystemic shunt placement.

Allegretti AS, Frenk NE, Li DK, Seethapathy H, Vela Parada XF, Long J, Endres P, Pratt DS, Chung RT, Ganguli S, Irani Z, Yamada K.

PLoS One. 2019 May 23;14(5):e0217442. doi: 10.1371/journal.pone.0217442. eCollection 2019.

6.

Balancing the risk and rewards of utilizing organs from hepatitis C viremic donors.

Sise ME, Strohbehn IA, Bethea E, Gustafson JL, Chung RT.

Curr Opin Organ Transplant. 2019 Jun;24(3):351-357. doi: 10.1097/MOT.0000000000000651.

PMID:
31090648
7.

Daily Aspirin Use Associated With Reduced Risk For Fibrosis Progression In Patients With Nonalcoholic Fatty Liver Disease.

Simon TG, Henson J, Osganian S, Masia R, Chan AT, Chung RT, Corey KE.

Clin Gastroenterol Hepatol. 2019 May 9. pii: S1542-3565(19)30493-8. doi: 10.1016/j.cgh.2019.04.061. [Epub ahead of print]

PMID:
31077838
8.

Balancing the risk and rewards of utilizing organs from hepatitis C viremic donors.

Sise ME, Strohbehn IA, Bethea E, Gustafson JL, Chung RT.

Curr Opin Organ Transplant. 2019 Apr 16. doi: 10.1097/MOT.0000000000000651. [Epub ahead of print]

PMID:
31008739
9.

Process of selecting and educating HCV-uninfected kidney waiting-list candidates for HCV-infected kidney transplantation.

Sise ME, Wojciechowski D, Chute DF, Gustafson J, Chung RT, Williams WW, Elias N.

Artif Organs. 2019 Apr 19. doi: 10.1111/aor.13473. [Epub ahead of print]

PMID:
31001828
10.

Microrna-130a Downregulates HCV Replication through an atg5-Dependent Autophagy Pathway.

Duan X, Liu X, Li W, Holmes JA, Kruger AJ, Yang C, Li Y, Xu M, Ye H, Li S, Liao X, Sheng Q, Chen D, Shao T, Cheng Z, Kaj B, Schaefer EA, Li S, Chen L, Lin W, Chung RT.

Cells. 2019 Apr 10;8(4). pii: E338. doi: 10.3390/cells8040338.

11.

Physicians' Perspectives on Palliative Care for Patients With End-Stage Liver Disease: A National Survey Study.

Ufere NN, Donlan J, Waldman L, Patel A, Dienstag JL, Friedman LS, Corey KE, Hashemi N, Carolan P, Mullen AC, Thiim M, Bhan I, Nipp R, Greer J, Temel J, Chung RT, El-Jawahri A.

Liver Transpl. 2019 Jun;25(6):859-869. doi: 10.1002/lt.25469. Epub 2019 May 3.

PMID:
30963669
12.

Barriers to Use of Palliative Care and Advance Care Planning Discussions for Patients With End-Stage Liver Disease.

Ufere NN, Donlan J, Waldman L, Dienstag JL, Friedman LS, Corey KE, Hashemi N, Carolan P, Mullen AC, Thiim M, Bhan I, Nipp R, Greer JA, Temel JS, Chung RT, El-Jawahri A.

Clin Gastroenterol Hepatol. 2019 Mar 15. pii: S1542-3565(19)30286-1. doi: 10.1016/j.cgh.2019.03.022. [Epub ahead of print]

PMID:
30885884
13.

Relationship between resolution of non-alcoholic steatohepatitis and changes in lipoprotein sub-fractions: a post-hoc analysis of the PIVENS trial.

Corey KE, Wilson LA, Altinbas A, Yates KP, Kleiner DE, Chung RT, Krauss RM, Chalasani N; NASH Clinical Research Network.

Aliment Pharmacol Ther. 2019 May;49(9):1205-1213. doi: 10.1111/apt.15216. Epub 2019 Mar 10.

PMID:
30854694
14.

Host Genetic Variant in CXCL16 May Be Associated With Hepatitis B Virus-Related Acute Liver Failure.

Ajmera V, Huang H, Dao D, Feld JJ, Lau DT, Patel K, Rule JA, Daly M, Lee WM, Chung RT.

Cell Mol Gastroenterol Hepatol. 2019;7(2):477-479.e4. doi: 10.1016/j.jcmgh.2018.09.018. Epub 2018 Oct 17. No abstract available.

15.

Outcomes of in-hospital cardiopulmonary resuscitation for patients with end-stage liver disease.

Ufere NN, Brahmania M, Sey M, Teriaky A, El-Jawahri A, Walley KR, Celi LA, Chung RT, Rush B.

Liver Int. 2019 Feb 27. doi: 10.1111/liv.14079. [Epub ahead of print]

PMID:
30809903
16.

Direct-acting antiviral treatment for hepatitis C.

Holmes JA, Rutledge SM, Chung RT.

Lancet. 2019 Apr 6;393(10179):1392-1394. doi: 10.1016/S0140-6736(18)32326-2. Epub 2019 Feb 11. No abstract available.

PMID:
30765125
17.

The immunity-related GTPase M rs13361189 variant does not increase the risk for prevalent or incident steatosis; results from the Framingham Heart Study.

Simon TG, Deng X, Liu CT, Chung RT, Long MT.

Liver Int. 2019 Jun;39(6):1022-1026. doi: 10.1111/liv.14039. Epub 2019 Feb 17.

PMID:
30597691
18.

Multi-Ancestry Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus.

Vergara C, Thio CL, Johnson E, Kral AH, O'Brien TR, Goedert JJ, Mangia A, Piazzolla V, Mehta SH, Kirk GD, Kim AY, Lauer GM, Chung RT, Cox AL, Peters MG, Khakoo SI, Alric L, Cramp ME, Donfield SM, Edlin BR, Busch MP, Alexander G, Rosen HR, Murphy EL, Latanich R, Wojcik GL, Taub MA, Valencia A, Thomas DL, Duggal P.

Gastroenterology. 2019 Apr;156(5):1496-1507.e7. doi: 10.1053/j.gastro.2018.12.014. Epub 2018 Dec 26.

PMID:
30593799
19.

Overview of Direct-Acting Antiviral Drugs and Drug Resistance of Hepatitis C Virus.

Li DK, Chung RT.

Methods Mol Biol. 2019;1911:3-32. doi: 10.1007/978-1-4939-8976-8_1. Review.

PMID:
30593615
20.

Phenotype and function of HBV-specific T cells is determined by the targeted epitope in addition to the stage of infection.

Hoogeveen RC, Robidoux MP, Schwarz T, Heydmann L, Cheney JA, Kvistad D, Aneja J, Melgaço JG, Fernandes CA, Chung RT, Boonstra A, Kim AY, Baumert TF, Timm J, Lewis-Ximenez LL, Tonnerre P, Lauer GM.

Gut. 2019 May;68(5):893-904. doi: 10.1136/gutjnl-2018-316644. Epub 2018 Dec 22.

PMID:
30580250
21.

Use of Hepatitis C Positive Organs: Patient Attitudes in Urban Chicago.

Couri T, Cotter TG, Chen D, Hammes M, Reddy B, Josephson M, Yeh H, Chung RT, Paul S.

Am J Nephrol. 2019;49(1):32-40. doi: 10.1159/000495263. Epub 2018 Dec 14.

PMID:
30554209
22.

Entecavir and Peginterferon Alfa-2a in Adults With Hepatitis B e Antigen-Positive Immune-Tolerant Chronic Hepatitis B Virus Infection.

Feld JJ, Terrault NA, Lin HS, Belle SH, Chung RT, Tsai N, Khalili M, Perrillo R, Cooper SL, Ghany MG, Janssen HLA, Lok AS; Hepatitis B Research Network.

Hepatology. 2019 Jun;69(6):2338-2348. doi: 10.1002/hep.30417. Epub 2019 Mar 14.

PMID:
30549279
23.

Antiviral activity of bone morphogenetic proteins and activins.

Eddowes LA, Al-Hourani K, Ramamurthy N, Frankish J, Baddock HT, Sandor C, Ryan JD, Fusco DN, Arezes J, Giannoulatou E, Boninsegna S, Chevaliez S, Owens BMJ, Sun CC, Fabris P, Giordani MT, Martines D, Vukicevic S, Crowe J, Lin HY, Rehwinkel J, McHugh PJ, Binder M, Babitt JL, Chung RT, Lawless MW, Armitage AE, Webber C, Klenerman P, Drakesmith H.

Nat Microbiol. 2019 Feb;4(2):339-351. doi: 10.1038/s41564-018-0301-9. Epub 2018 Dec 3.

PMID:
30510168
24.

Dynamic changes in innate immune responses during direct-acting antiviral therapy for HCV infection.

Holmes JA, Carlton-Smith C, Kim AY, Dumas EO, Brown J, Gustafson JL, Lauer GM, Silva ST, Robidoux M, Kvistad D, Alatrakchi N, Tonnerre P, Cohen DE, Zhang H, Shulman NS, Chung RT.

J Viral Hepat. 2019 Mar;26(3):362-372. doi: 10.1111/jvh.13041. Epub 2019 Jan 3.

PMID:
30450781
25.

Spectrum of Liver Disease in Hepatitis B Virus (HBV) Patients Co-infected with Human Immunodeficiency Virus (HIV): Results of the HBV-HIV Cohort Study.

Sterling RK, Wahed AS, King WC, Kleiner DE, Khalili M, Sulkowski M, Chung RT, Jain MK, Lisker-Melman M, Wong DK, Ghany MG; HIV-HBV Cohort Study of the Hepatitis B Research Network.

Am J Gastroenterol. 2019 May;114(5):746-757. doi: 10.1038/s41395-018-0409-9.

PMID:
30410040
26.

Bone Morphogenetic Protein 9 Is a Mechanistic Biomarker of Portopulmonary Hypertension.

Nikolic I, Yung LM, Yang P, Malhotra R, Paskin-Flerlage SD, Dinter T, Bocobo GA, Tumelty KE, Faugno AJ, Troncone L, McNeil ME, Huang X, Coser KR, Lai CSC, Upton PD, Goumans MJ, Zamanian RT, Elliott CG, Lee A, Zheng W, Berasi SP, Huard C, Morrell NW, Chung RT, Channick RW, Roberts KE, Yu PB.

Am J Respir Crit Care Med. 2019 Apr 1;199(7):891-902. doi: 10.1164/rccm.201807-1236OC.

PMID:
30312106
27.

Association Between Aspirin Use and Risk of Hepatocellular Carcinoma.

Simon TG, Ma Y, Ludvigsson JF, Chong DQ, Giovannucci EL, Fuchs CS, Meyerhardt JA, Corey KE, Chung RT, Zhang X, Chan AT.

JAMA Oncol. 2018 Dec 1;4(12):1683-1690. doi: 10.1001/jamaoncol.2018.4154.

PMID:
30286235
28.

Detection and Analysis of Circulating Epithelial Cells in Liquid Biopsies From Patients With Liver Disease.

Bhan I, Mosesso K, Goyal L, Philipp J, Kalinich M, Franses JW, Choz M, Oklu R, Toner M, Maheswaran S, Haber DA, Zhu AX, Chung RT, Aryee M, Ting DT.

Gastroenterology. 2018 Dec;155(6):2016-2018.e11. doi: 10.1053/j.gastro.2018.09.020. Epub 2018 Sep 13. No abstract available.

PMID:
30218669
29.

Hepatic connexin 32 associates with nonalcoholic fatty liver disease severity.

Luther J, Gala MK, Borren N, Masia R, Goodman RP, Moeller IH, DiGiacomo E, Ehrlich A, Warren A, Yarmush ML, Ananthakrishnan A, Corey K, Kaplan LM, Bhatia S, Chung RT, Patel SJ.

Hepatol Commun. 2018 Jul 16;2(7):786-797. doi: 10.1002/hep4.1179. eCollection 2018 Jul.

30.

A Long Noncoding RNA Regulates Hepatitis C Virus Infection Through Interferon Alpha-Inducible Protein 6.

Liu X, Duan X, Holmes JA, Li W, Lee SH, Tu Z, Zhu C, Salloum S, Lidofsky A, Schaefer EA, Cai D, Li S, Wang H, Huang Y, Zhao Y, Yu ML, Xu Z, Chen L, Hong J, Lin W, Chung RT.

Hepatology. 2019 Mar;69(3):1004-1019. doi: 10.1002/hep.30266. Epub 2019 Feb 13.

PMID:
30199576
31.

Parental non-alcoholic fatty liver disease increases risk of non-alcoholic fatty liver disease in offspring.

Long MT, Gurary EB, Massaro JM, Ma J, Hoffmann U, Chung RT, Benjamin EJ, Loomba R.

Liver Int. 2019 Apr;39(4):740-747. doi: 10.1111/liv.13956. Epub 2018 Sep 25.

PMID:
30179294
32.

Serum Angiopoietin-2 Predicts Mortality and Kidney Outcomes in Decompensated Cirrhosis.

Allegretti AS, Vela Parada X, Ortiz GA, Long J, Krinsky S, Zhao S, Fuchs BC, Sojoodi M, Zhang D, Karumanchi SA, Kalim S, Nigwekar SU, Thadhani RI, Parikh SM, Chung RT.

Hepatology. 2019 Feb;69(2):729-741. doi: 10.1002/hep.30230. Epub 2019 Jan 4.

PMID:
30141205
33.

Cost Effectiveness of Transplanting HCV-Infected Livers Into Uninfected Recipients With Preemptive Antiviral Therapy.

Bethea ED, Samur S, Kanwal F, Ayer T, Hur C, Roberts MS, Terrault N, Chung RT, Chhatwal J.

Clin Gastroenterol Hepatol. 2019 Mar;17(4):739-747.e8. doi: 10.1016/j.cgh.2018.08.042. Epub 2018 Aug 21.

PMID:
30138735
34.

Heat Stroke as a Cause of Liver Failure and Evaluation of Liver Transplant.

Martins PN, Brüggenwirth IMA, McDaid J, Hertl M, Kawai T, Elias N, Chung RT, Markmann JF.

Exp Clin Transplant. 2018 Aug 17. doi: 10.6002/ect.2018.0003. [Epub ahead of print]

35.

Opioid Use Disorder, Stigma, and Transplantation: A Call to Action.

Wakeman SE, Ladin K, Brennan T, Chung RT.

Ann Intern Med. 2018 Aug 7;169(3):188-189. doi: 10.7326/M18-1099. Epub 2018 Jul 10. No abstract available.

PMID:
29987319
36.

The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe.

Simon TG, Corey KE, Cannon CP, Blazing M, Park JG, O'Donoghue ML, Chung RT, Giugliano RP.

Int J Cardiol. 2018 Nov 1;270:245-252. doi: 10.1016/j.ijcard.2018.05.087. Epub 2018 May 26.

PMID:
29903515
37.

Macrophage Activation Marker Soluble CD163 Is a Dynamic Marker of Liver Fibrogenesis in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection.

Lidofsky A, Holmes JA, Feeney ER, Kruger AJ, Salloum S, Zheng H, Seguin IS, Altinbas A, Masia R, Corey KE, Gustafson JL, Schaefer EA, Hunt PW, Deeks S, Somsouk M, Chew KW, Chung RT, Alatrakchi N.

J Infect Dis. 2018 Sep 22;218(9):1394-1403. doi: 10.1093/infdis/jiy331.

PMID:
29868909
38.

Patients With Cirrhosis Require More Fecal Microbiota Capsules to Cure Refractory and Recurrent Clostridium difficile Infections.

Pringle PL, Soto MT, Chung RT, Hohmann E.

Clin Gastroenterol Hepatol. 2019 Mar;17(4):791-793. doi: 10.1016/j.cgh.2018.05.038. Epub 2018 May 31.

PMID:
29859984
39.

IRGM Gene Variants Modify the Relationship Between Visceral Adipose Tissue and NAFLD in Patients With Crohn's Disease.

Simon TG, Van Der Sloot KWJ, Chin SB, Joshi AD, Lochhead P, Ananthakrishnan AN, Xavier R, Chung RT, Khalili H.

Inflamm Bowel Dis. 2018 Sep 15;24(10):2247-2257. doi: 10.1093/ibd/izy128.

PMID:
29788077
40.

Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet-induced mouse model of nonalcoholic steatohepatitis.

Kruger AJ, Fuchs BC, Masia R, Holmes JA, Salloum S, Sojoodi M, Ferreira DS, Rutledge SM, Caravan P, Alatrakchi N, Vig P, Lefebvre E, Chung RT.

Hepatol Commun. 2018 Mar 7;2(5):529-545. doi: 10.1002/hep4.1160. eCollection 2018 May.

41.

Reactivation of a Vaccine Escape Hepatitis B Virus Mutant in a Cambodian Patient During Anti-Hepatitis C Virus Therapy.

Fusco DN, Ganova-Raeva L, Khudyakov Y, Punkova L, Mohamed A, Cheon SSY, Koirala P, Andersson KL, Jourdain G, Sureau C, Chung RT, Lauer G.

Front Med (Lausanne). 2018 Apr 30;5:97. doi: 10.3389/fmed.2018.00097. eCollection 2018.

42.

Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate.

MacBrayne CE, Marks KM, Fierer DS, Naggie S, Chung RT, Hughes MD, Kim AY, Peters MG, Brainard DM, Seifert SM, Castillo-Mancilla JR, Bushman LR, Anderson PL, Kiser JJ.

J Antimicrob Chemother. 2018 Aug 1;73(8):2112-2119. doi: 10.1093/jac/dky146.

PMID:
29746648
43.

Treatment of hepatitis C virus infection in patients with mixed cryoglobulinemic syndrome and cryoglobulinemic glomerulonephritis.

Rutledge SM, Chung RT, Sise ME.

Hemodial Int. 2018 Apr;22 Suppl 1:S81-S96. doi: 10.1111/hdi.12649. Review.

PMID:
29694729
44.

Transplantation of hepatitis C virus infected kidneys into hepatitis C virus uninfected recipients.

Sise ME, Chute DF, Gustafson JL, Wojciechowski D, Elias N, Chung RT, Williams WW.

Hemodial Int. 2018 Apr;22 Suppl 1:S71-S80. doi: 10.1111/hdi.12650. Review.

PMID:
29694722
45.

Reply.

Chhatwal J, Bethea ED, Samur S, Chung RT.

Hepatology. 2018 Aug;68(2):793. doi: 10.1002/hep.30042. No abstract available.

PMID:
29672882
46.

Relationship Between Metabolic Syndrome, Alanine Aminotransferase Levels, and Liver Disease Severity in a Multiethnic North American Cohort With Chronic Hepatitis B.

Khalili M, Shuhart MC, Lombardero M, Feld JJ, Kleiner DE, Chung RT, Terrault NA, Lisker-Melman M, Sanyal A, Lok AS; Hepatitis B Research Network (HBRN); Harvard Consortium.

Diabetes Care. 2018 Jun;41(6):1251-1259. doi: 10.2337/dc18-0040. Epub 2018 Mar 29.

47.

Circulating Interleukin-6 is a biomarker for coronary atherosclerosis in nonalcoholic fatty liver disease: Results from the Multi-Ethnic Study of Atherosclerosis.

Simon TG, Trejo MEP, McClelland R, Bradley R, Blaha MJ, Zeb I, Corey KE, Budoff MJ, Chung RT.

Int J Cardiol. 2018 May 15;259:198-204. doi: 10.1016/j.ijcard.2018.01.046.

48.

Tyrosine kinase SYK is a potential therapeutic target for liver fibrosis.

Qu C, Zheng D, Li S, Liu Y, Lidofsky A, Holmes JA, Chen J, He L, Wei L, Liao Y, Yuan H, Jin Q, Lin Z, Hu Q, Jiang Y, Tu M, Chen X, Li W, Lin W, Fuchs BC, Chung RT, Hong J.

Hepatology. 2018 Mar 14. doi: 10.1002/hep.29881. [Epub ahead of print]

PMID:
29537660
49.

Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B.

Jourdain G, Ngo-Giang-Huong N, Harrison L, Decker L, Khamduang W, Tierney C, Salvadori N, Cressey TR, Sirirungsi W, Achalapong J, Yuthavisuthi P, Kanjanavikai P, Na Ayudhaya OP, Siriwachirachai T, Prommas S, Sabsanong P, Limtrakul A, Varadisai S, Putiyanun C, Suriyachai P, Liampongsabuddhi P, Sangsawang S, Matanasarawut W, Buranabanjasatean S, Puernngooluerm P, Bowonwatanuwong C, Puthanakit T, Klinbuayaem V, Thongsawat S, Thanprasertsuk S, Siberry GK, Watts DH, Chakhtoura N, Murphy TV, Nelson NP, Chung RT, Pol S, Chotivanich N.

N Engl J Med. 2018 Mar 8;378(10):911-923. doi: 10.1056/NEJMoa1708131.

50.

Tricyclic antidepressant use and the risk of fibrosis progression in hepatitis C-infected persons: Results from ERCHIVES.

Chen JY, Ren Y, Yan P, Belina ME, Chung RT, Butt AA.

J Viral Hepat. 2018 Jul;25(7):825-833. doi: 10.1111/jvh.12884. Epub 2018 Mar 22.

PMID:
29478294

Supplemental Content

Loading ...
Support Center